Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: A retrospective cohort study

Clinical Drug Investigation

Volumn 31, Issue 2, 2011, Pages 113-120

  Gobin, Jaya ^a   Cernii, Aura ^a   McLean, Rosella ^a   Finkelstein, Fredric O ^a   Simon, David B ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

Anaemia, treatment; Darbepoetin alfa, therapeutic use; Epoetin alfa, therapeutic use; Eythropoiesis stimulants, therapeutic use; Kidney disorders, treatment

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; COMMUNITY HOSPITAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; COMMUNITY HEALTH CENTERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 78650268724     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11584460-000000000-00000     Document Type: Article

References (19)

1. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47 Suppl. 3: S11-45
2. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501-10 (Pubitemid 39361354)
3. Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61 (Pubitemid 26231466)
4. Pereira BJG. Overcoming barriers to the early detection and treatment of chronic kidney disease and improving outcomes for end-stage renal disease. Am J Manage Care 2002; 8 Suppl. 4: S122-35
5. Padhi D,Ni L, Cooke B, et al. An extended terminal half-life for darbepoetin alfa. Clin Pharmacokinet 2006; 45 (5): 503-10
6. Kampf D, Eckardt KU, Fischer HC, et al. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 1992; 61 (4): 393-8
7. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in RenalDisease StudyGroup.Ann Intern Med 1999; 130 (6): 461-70
8. Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005; 64: 113-23 (Pubitemid 41079007)
9. McGowan T, Vaccaro NM, Beaver JS, et al. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008; 3: 1006-14
10. Spinowitz B, Germain M, Benz R, et al. Randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1015-21
11. Germain M, Ram CV, Bhaduri S, et al. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant 2005; 20: 146-52 (Pubitemid 41510090)
12. Padhi D, Ni L, Cooke B, et al. An extended terminal halflife for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006; 45 (5): 503-10
13. Ling B, Walczyk M, Agarwal A, et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005; 63 (5): 327-34 (Pubitemid 40668225)
14. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-98 (Pubitemid 44749317)
15. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-84 (Pubitemid 44749316)
16. Pfeffer MA, Burdmann EA, Chen CY, et al., TREAT Investigators. Atrial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-32
17. Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 33-8
18. Leaf DE, Goldfarb DS. Interpretation and review of healthrelated quality of life data in CKD patients receiving treatment for anemia. Kidney Int 2009; 75: 15-23
19. Horowitz J, Agarwal A, Huang F, et al. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. J Manag Care Pharm 2009; 15: 741-50